Screener
Immunome IMNM Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accrued expenses and other current liabilities | (9,746) | (8,521) |
| Deferred revenue | — | (2,926) |
| Operating lease liabilities | (161) | (62) |
| Net cash used in operating activities | (58,638) | (53,055) |
| Cash flows from investing activities: | ||
| Purchases of in-process research and development assets | (9,014) | (6,246) |
| Purchases of property and equipment | (3,002) | (3,665) |
| Maturities of marketable securities | — | 15,000 |
Item 1. Financial Statements.
FAQ
- What is Immunome's operating cash flow?
- Immunome (IMNM) reported operating cash flow of -$58.64M in Q1 2026.
- How has Immunome's operating cash flow changed year-over-year?
- Immunome's operating cash flow decreased by 10.5% year-over-year, from -$53.06M to -$58.64M.
- What is the long-term trend for Immunome's operating cash flow?
- Over 3 years (2021 to 2025), Immunome's operating cash flow has grown at a 118.8% compound annual growth rate (CAGR), from -$18.23M to -$190.92M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Immunome's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude